Inguinal Lymphadenopathy: A Rare Initial Site of Metastatic Lung Carcinoma

Abhishek Mahato1  Gaurav P.S. Gahlot2  Deepak Kumar Jha3  Rajhans4

1Department of Nuclear Medicine and PET/CT, Command Hospital Lucknow, Lucknow Cantonment, Uttar Pradesh, India
2Department of Oncopathology, Command Hospital Chandimandir, Panchkula, Haryana, India
3Department of Nuclear Medicine and PET/CT, Army Hospital R&R, New Delhi, Delhi, India
4Department of Radiation Oncology, Army Hospital R&R, New Delhi, Delhi, India

Address for correspondence Abhishek Mahato, DNB, Department of Nuclear Medicine and PET/CT, Command Hospital Lucknow, Lucknow Cantonment, 226002, Uttar Pradesh, India (e-mail: dr.abhi22ndleo@gmail.com).

Case Presentation

A 59-year-old male presented with weight loss and chronic productive cough in the last 6 months. The patient was a chronic smoker for 40 years, using 50 bidis (tobacco wrapped in tendu or temburni leaf and hand-rolled) per month. Radiograph of the chest revealed an opacity in the right upper zone extending till the mediastinum. Clinical differentials of lung carcinoma and pulmonary tuberculosis were considered. On further evaluation, the patient had microcytic hypochromic anemia with a hemoglobin of 9.1 g/dL, while liver function and kidney function tests were preserved for his age. Negative results of Mantoux test and Mycobacterium tuberculosis polymerase chain reaction excluded pulmonary tuberculosis.

The computed tomography (CT) of the chest revealed a large, soft tissue density mass lesion involving the anterior segment of right upper lobe. The lesion was abutting the costal pleura along the right third–sixth rib posteriorly with mediastinal infiltration on the medial side; however, no obvious pleural/chest wall infiltration was appreciable. CT scan findings were suggestive of a neoplastic etiology likely carcinoma lung stage—T4N2M0. CT-guided biopsy was performed and based on histopathological and...
inguinal lymph node (also showed an intense FDG-avid focus in an enlarged left mous cell carcinoma lung was made (deposits of poorly differentiated carcinoma (of the lymph node was performed, revealing metastatic inguinal lymph nodal metastases was concluded. A second primary, a diagnosis of carcinoma lung with left else where in the scanned region of the body ruling out deposits of poorly differentiated carcinoma. Relevant physical examination of ano-rectum, penis, and lower limb was performed; contrast-enhanced CT of the abdomen and pelvis did not reveal any abnormality. This case was discussed in the tumor board of the hospital as a case of carcinoma lung with oligometastatic involvement of left inguinal lymph nodes—stage T4N2M1b. The tumor board was of divided opinion on the line of management shuffling between curative intent and palliative care. Although the final decision shifted toward a palliative care, a significant majority were for curative intent based on the newer concept of oligometastatic disease. The patient was started on palliative chemo-radiotherapy; however, despite limited tumor burden the patient succumbed to his illness within a year of initiation of treatment.

Discussion

Lung cancer is the most commonly diagnosed cancer in males and the leading cause of cancer death.1 Lung carcinoma is broadly divided into two main categories, that is, non-small cell lung carcinoma (NSCLC; 80–85%) and small cell lung carcinoma (SCLC; 15%). In total, 30 to 40% of NSCLC patients have metastatic disease to contralateral lungs, brain, liver, and adrenal glands at the time of diagnosis.2,3 Tamura et al noted that among the consecutive 1,542 NSCLC patients, 47.3% of all cases presented with distant metastasis to bone (34.3%), lung (32.1%), brain (28.4%), adrenal gland (16.7%), liver (13.4%), and extrathoracic lymph node (9.5%) sites, respectively.4 Metastasis of NSCLC to inguinal lymph nodes is extremely rare and solid-organ tumors involving inguinal lymph nodes commonly originate from genitourinary tract, skin, ano-rectum, or urinary bladder.5 While surgery is preferred for NSCLC in initial stages, metastatic cases of NSCLC are

immunohistochemical findings a final diagnosis of squamous cell carcinoma lung was made (Fig. 1A).

As a part of routine protocol, whole body 18F-FDG PET-CT (fluoro deoxy glucose positron emission tomography-computed tomography) scan from base of skull to mid-thigh was performed with Siemens Symbia T6 after 45 minutes after intravenous injection of 370MBq of 18F-FDG. CT images were acquired by a whole-body full-ring dedicated lutetium oxy-orthosilicate PET/CT scanner using 130 KV and 90 mAs−1 without administration of intravenous or oral contrast. Images were reconstructed using standard iterative algorithm—Ordered Subset Expectation Maximization (OSEM)—and reformatted into transaxial, coronal, and sagittal views. The FDG-avid findings of PET-CT scan were in consistence with the findings of CT chest (Fig. 1B, C); however, PET-CT also showed an intense FDG-avid focus in an enlarged left inguinal lymph node (Fig. 1C, D). No other abnormal FDG-avid focus was noted in the contralateral lung, liver, adrenals, or axial and appendicular skeleton, and in the abdominopelvic region. Therefore, in the absence of abnormal FDG avidity elsewhere in the scanned region of the body ruling out a second primary, a diagnosis of carcinoma lung with left inguinal lymph nodal metastases was concluded.

Based on PET-CT findings, fine needle aspiration cytology of the lymph node was performed, revealing metastatic deposits of poorly differentiated carcinoma (Fig. 1E). Since solitary involvement of inguinal lymph nodes from carcino ma lung is an extremely uncommon finding, search for a second primary was considered. Relevant physical examination of ano-rectum, penis, and lower limb was performed; contrast-enhanced CT of the abdomen and pelvis did not

Fig. 1 (A) 400 × H&E-stained sections showed tumor cells arranged in nests, islands, and singly scattered patterns. The individual tumor cells show well-defined cell borders with moderate eosinophilic cytoplasm squamoid morphology with polygonal shape, round to oval hyperchromatic nuclei, mild to moderate nuclear polymorphism, and prominent nucleoli. (B) Axial section of FDG PET-CT at the level of mid-thorax showing FDG-avid mass in right lung invading the mediastinum. (C) Maximum intensity projection (MIP) images of FDG PET-CT showing FDG-avid right lung mass and left inguinal lymphadenopathy. (D) Axial section of FDG PET-CT at the level of upper thigh depicting intense FDG avid left inguinal lymph node. (E) 200 × FNAC of left inguinal lymph node was performed with LG (Leishman–Giemsa) stain. FNAC smears showed tumor cells arranged in small sheets, clusters, and singly scattered pattern. The individual tumor cells have round to oval nuclei and moderate to marked nuclear polymorphism. FNAC, fine needle aspiration cytology.
Inguinal Lymphadenopathy: A Rare Initial Site of Metastatic Lung Carcinoma

Mahato et al.

Table 1: A comparative feature of the three cases of NSCLC with inguinal lymph node metastases cited in the English literature

| Parameters                        | Kocak et al. | Grandić et al. | Present case |
|-----------------------------------|--------------|----------------|--------------|
| Age (y)                           | 58           | 67             | 59           |
| Gender                            | Male         | Male           | Male         |
| Lung affected                     | Right perihilar | Right perihilar | Right upper lobe mass with hilar involvement |
| NSCLC type                        | Squamous cell carcinoma | Squamous cell carcinoma | Squamous cell carcinoma |
| CT chest staging                  | T4N2M0       | T3N2M0         | T4N2M0       |
| 18F-FDG PET-CT                    | Not performed | Not performed  | T4N2M1b      |
| Inguinal lymph node affected      | Right        | Bilateral inguinal lymph node | Left         |
| Time line in which inguinal lymph node was found | 5 months after diagnosis and treatment | After few months of treatment | Initial staging |
| Other site of metastases reported | Nil          | Liver and lumbosacral spine after few months of treatment | Nil          |
| Overall survival                  | 1 y (approx.) | 1 y (approx.)  | 9 mo         |

managed with palliative chemo-radiotherapy. Such patients have a 5-year survival chance of less than 5% despite chemo and radiation therapy.

Our extensive literature search could find only five cases of solid-organ tumor involving inguinal lymph nodes that have been reported ante-mortem in the English literature with primary being lung cancer, malignant mesothelioma, and salivary duct and breast carcinoma. Only two articles cited involvement of inguinal lymph nodes from primary lung cancer. One by Grandić et al who reported inguinal lymph node metastases as the first sign of disease relapse following remission of primary lung cancer. Second case report is by Kocak et al who observed inguinal lymph node as the only evidence of progressive lung cancer. The inclusion of the term “oligometastatic disease” by the International Association for the Study of Lung Cancer in its eighth edition signifies the paradigm shift happening in the management of lung cancer. The classification divides patients into three distinct categories based on the prognosis: stage M1a: involvement of the lung alone; M1b: single extrathoracic metastasis; and M1c: multiple extrathoracic metastases in one or more organs.

First described by Hellman and Weichselbaum in 1995, oligometastasis refers to a clinical stage in which patients present a limited number of metastases to a few sites (a single organ or a few organs). These patients have a better prognosis than patients presenting with multiple metastases. The oligometastatic group represents 20 to 50% of patients with NSCLC depending upon the specific definition and time of presentation.

We hereby report the first ever case of synchronous oligometastatic carcinoma lung with solitary involvement of left inguinal lymph node. The case highlights the advantage FDG PET-CT has over traditional imaging modalities in delineating the oligometastatic subgroup of patients. Although the patient was managed with palliative treatment, a substantial majority in the hospital tumor board were of the opinion to enroll and treat the patient as oligometastatic disease with a curative intent. However, the final decision taken was of palliative management due to lack of experience in managing oligometastatic disease and also of definite guidelines which are still in phase II trials. The rapid progression of the disease with no response to the palliative line of care suggests adaptation of the new paradigm shift with informed patient consent and enrolment into clinical trials.

Conclusion

The index case showcases one of the rare presentations of carcinoma lung. Based on our extensive literature search, we claim this to be the first ever case reported of a de-novo or synchronous oligometastatic disease of carcinoma lung with inguinal lymph node involvement.

The case emphasizes the critical role played by 18F-FDG PET-CT as an essential work-up tool for metastatic work-up of malignancies. FDG PET-CT was the decisive imaging modality in this case. The article also points out that special emphasis should be given to any suspicious abnormal FDG-avid focus on a PET-CT scan. In absence of the FDG PET-CT, the metastatic disease would have been missed. In fact, since the other two case reports had the disadvantage of not having FDG PET, therefore the possibility of inguinal metastases at the initial presentation cannot be excluded in them.

As per latest American Joint Committee on Cancer guidelines, involvement of nonregional lymph nodes upstages the disease to stage M1b. Such patients have a 5-year survival chance of less than 5% despite chemo and radiation therapy. With the concept of oligometastatic disease, such patient population should be admitted into a trial of curative management rather than subjecting them to palliative care.
Conflict of Interest
None.

References
1. World Health Organization. Accessed at: https://www.who.int/news-room/fact-sheets/detail/cancer
2. Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto. Japan Cancer Surveillance Research Group. Cancer incidence and incidence rates in Japan in 2008: a study of 25 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCJ) project. Jpn J Clin Oncol 2014;44(04):388–396
3. Little AG, Gay EG, Gaspar LE, Stewart AK. National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care. Lung Cancer 2007;57(03):253–260
4. Tamura T, Kurishima K, Nakazawa K, et al. Specific organ metastases and survival in metastatic non-small-cell lung cancer. Mol Clin Oncol 2015;3(01):217–221
5. Kaya C, Tanrikulu H, Yilmaz G, Aker F, Karaman Ml. Spermatic cord metastasis as an initial manifestation of non-small cell carcinoma of the lung. Int J Urol 2006;13(06):846–848
6. Kalemerkian GP, Pass HI. Lung cancer: present concepts in the molecular biology of lung cancer. In: Shields TW, Locicero J, Ponn RB, eds. General Thoracic Surgery, 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:1235–1268
7. Nesbitt JC, Putnam JB Jr, Walsh GL, Roth JA, Mountain CF. Survival in early-stage non-small cell lung cancer. Ann Thorac Surg 1995;60(02):466–472
8. Ota T, Shinohara M, Tanaka M, et al. Spermatic cord metastases from gastric cancer with elevation of serum hCG-beta: a case report. Jpn J Clin Oncol 2000;30(05):239–240
9. U.S. National Institute Of Health, National Cancer Institute. Seer cancer statistics review, 1975–2015.
10. Kocak Z, Saynak M, Oz-Puyan F, et al. Inguinal lymph node as the only evidence of progressive lung cancer. Rev Port Pneumol 2008;14(05):709–713
11. Grandić L, Pogorelić Z, Banović J, Forempoher G, Ilić N, Perko Z. Atypical non-small cell lung cancer presentation: inguinal lymph node metastases as the first sign of disease relapse. Acta Clin Croat 2010;49(04):441–444
12. Eberhardt WE, Mitchell A, Crowley J, et al; Rami-Porta R International Association for Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members, and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol 2015;10(11):1515–1522
13. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995;13(01):8–10
14. Bergsma DP, Salama JK, Singh DP, Chmura SJ, Milano MT. Radiotherapy for oligometastatic lung cancer. Front Oncol 2017;7:210
15. Couñago F, Luna J, Guerrero LL, et al. Management of oligometastatic non-small cell lung cancer patients: current controversies and future directions. World J Clin Oncol 2019;10(10):318–339